期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/ijms23031184
关键词
neurodegeneration; microbiome; stem cells; epigenetics; neurological disorders
资金
- National Institutes of Health (NIH) [R01NS090962, R01NS102395, R21NS109575, RF1AG071762, R21AG072379, R56AG064075]
- USF Center for Microbiome Research
- Department of Defense [W81XWH-18-PRARP-NIRA]
Human lifestyle and dietary behaviors contribute to the development of diseases, including neurodegenerative diseases. Changes in the gut microbiome have been associated with neurodegenerative diseases, and the inflammation associated with the gut microbiome plays a role in the development and prognosis of these diseases. The gut-brain axis represents an underexplored area for developing therapies for neurodegenerative diseases.
Human lifestyle and dietary behaviors contribute to disease onset and progression. Neurodegenerative diseases (NDDs), considered multifactorial disorders, have been associated with changes in the gut microbiome. NDDs display pathologies that alter brain functions with a tendency to worsen over time. NDDs are a worldwide health problem; in the US alone, 12 million Americans will suffer from NDDs by 2030. While etiology may vary, the gut microbiome serves as a key element underlying NDD development and prognosis. In particular, an inflammation-associated microbiome plagues NDDs. Conversely, sequestration of this inflammatory microbiome by a correction in the dysbiotic state of the gut may render therapeutic effects on NDDs. To this end, treatment with short-chain fatty acid-producing bacteria, the main metabolites responsible for maintaining gut homeostasis, ameliorates the inflammatory microbiome. This intimate pathological link between the gut and NDDs suggests that the gut-brain axis (GBA) acts as an underexplored area for developing therapies for NDDs. Traditionally, the classification of NDDs depends on their clinical presentation, mostly manifesting as extrapyramidal and pyramidal movement disorders, with neuropathological evaluation at autopsy as the gold standard for diagnosis. In this review, we highlight the evolving notion that GBA stands as an equally sensitive pathological marker of NDDs, particularly in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and chronic stroke. Additionally, GBA represents a potent therapeutic target for treating NDDs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据